Description
Evkeeza (evinacumab) is a prescription medication used to treat patients with homozygous familial hypercholesterolemia (HoFH), a rare genetic condition that results in extremely high levels of low-density lipoprotein cholesterol (LDL-C) in the blood. It is an intravenous medication that works by binding and neutralizing a protein called angiopoietin-like 3 (ANGPTL3), which is responsible for regulating cholesterol and triglyceride levels. Evkeeza is manufactured by Regeneron Pharmaceuticals and is only available through a restricted distribution program.
Uses:
Evkeeza is used to lower LDL-C levels in patients with HoFH who have not responded to other cholesterol-lowering therapies. The medication can help reduce the risk of heart attacks and other cardiovascular complications associated with high LDL-C levels.
Storage Conditions:
Evkeeza should be stored in a refrigerator at a temperature between 2℃ and 8℃ (36℉ to 46℉). The medication should be protected from light and excessive heat. The medication should be kept in its original packaging until it is ready to be used. Patients should not freeze this medication.
Mechanism of Action:
Evkeeza works by binding and neutralizing a protein called angiopoietin-like 3 (ANGPTL3), which is an inhibitor of lipoprotein lipase and endothelial lipase. ANGPTL3 deficiency leads to decreased inhibition of these enzymes and leads to reduced levels of circulating cholesterol and triglycerides.
HOW TO USE:
Evkeeza is given as a 420 mg intravenous infusion every four weeks. The medication should be administered by a healthcare provider in a medical setting. The infusion should be given over a period of approximately one hour. Patients may receive premedication before the infusion to prevent allergic reactions. The patient’s LDL-C levels should be monitored regularly during treatment.
Precautions:
Patients should inform their healthcare provider of any allergies or medical conditions before receiving Evkeeza. The medication should not be used in patients with a known hypersensitivity to evinacumab or any of its components. Patients with severe renal disease or receiving dialysis should use the medication with caution.
Drug Interactions:
Currently, there are no known drug interactions with Evkeeza. However, patients should inform their healthcare provider of any other medications they are taking.
Contraindications:
Evkeeza should not be used in patients with a known hypersensitivity to evinacumab or any of its components. Additionally, it should not be used in patients with moderate or severe hepatic impairment.
Overdose:
Currently, there is limited information on the specific symptoms that may occur with an Evkeeza overdose. In case of an overdose, patients should seek medical attention immediately.
Adverse Reactions:
Common adverse reactions of Evkeeza may include infections, flu-like symptoms, or infusion site reactions. Less common adverse reactions may include hypersensitivity reactions. Patients should report any adverse reactions to their healthcare provider.
In conclusion, Evkeeza (evinacumab) is an intravenous medication used to treat patients with HoFH, a rare genetic condition that results in extremely high LDL-C levels. It works by binding and neutralizing angiopoietin-like 3 (ANGPTL3), which is responsible for regulating cholesterol and triglyceride levels. Evkeeza is given as a 420 mg infusion every four weeks and is only available through a restricted distribution program. Patients with known hypersensitivity or moderate to severe hepatic impairment should not take the medication. Proper storage conditions should be maintained and patients should report any adverse reactions to their healthcare provider.
Reviews
There are no reviews yet.